CBO Report Highlights ACA Fraud; Legislation Targets Subsidy Abuse
CBO analysis reveals 2.3M fraudulent enrollees in ACA, prompting legislative reforms to curb subsidy abuse and enhance federal health program integrity.
CBO analysis reveals 2.3M fraudulent enrollees in ACA, prompting legislative reforms to curb subsidy abuse and enhance federal health program integrity.
Monthly premiums on Pennsylvania's ACA exchange may spike up to 300% if federal enhanced premium tax credits expire, affecting 450,000+ enrollees and market stability.
Explore the implications of the 2025 decision on ACA enhanced tax credits that impacts health insurance affordability for 24 million Americans and federal health policy.
ACA health insurance premiums are set to rise sharply in 2026 as enhanced premium subsidies expire, with insurers citing medical inflation and drug costs. Congressional action is uncertain amid strong public support for subsidy extension.
A federal judge blocks major provisions of CMS's new ACA Marketplace rule, pausing stricter eligibility checks and subsidy limits that affect coverage for 1.8 million people.
AM Best revises US health insurance outlook to negative due to rising medical utilization, increased specialty drug use, and regulatory challenges impacting Medicare Advantage and Medicaid programs. Premiums projected to rise up to 60% by 2025.
Health insurance premiums in the US are rising rapidly due to increased healthcare costs and policy changes, impacting affordability and coverage stability.
Pharmaceutical import tariffs are driving up health insurance premiums in the ACA small group market, as insurers anticipate higher drug costs and incorporate these risks into rate filings. This impacts employer health benefits and premium affordability.
Health insurers warn of significant premium hikes for ACA individual plans in 2026 if Congress does not extend enhanced tax credits, risking coverage loss for millions.
Federal court temporarily blocks key CMS rule on ACA health insurance exchange enrollment and eligibility pending further legal review, creating regulatory uncertainty.